Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Jnj-39393406. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 6/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 5/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Jnj-39393406 SCHEMBL827762 | 1.00 | KDM4E (0.39) | KDM4EALDH1A1BRAFJAK2JAK3 | |
| SCHEMBL827982 | 0.91 | CYP1A2 (0.39) | KDM4EALDH1A1BRAFJAK2JAK3 | |
| SCHEMBL827668 | 0.89 | CYP1A2 (0.38) | KDM4EALDH1A1BRAFJAK2JAK3 | |
| SCHEMBL829454 | 0.79 | IDH2 (0.43) | KDRRECQL | |
| SCHEMBL1514237 | 0.77 | BRAF (0.39) | KDM4EALDH1A1BRAFCYP1A2KIT | |
| SCHEMBL827708 | 0.75 | CYP1A2 (0.42) | BRAFCYP1A2ADORA3ADORA2AADORA2B | |
| SCHEMBL827495 | 0.74 | CYP1A2 (0.43) | BRAFCYP1A2ADORA3ADORA2AADORA2B | |
| SCHEMBL3782936 | 0.74 | JAK2 (0.38) | KDM4EALDH1A1BRAFJAK2JAK3 | |
| SCHEMBL12450325 | 0.73 | CYP1A2 (0.42) | KDM4EALDH1A1BRAFCYP1A2ADORA3 | |
| SCHEMBL827727 | 0.73 | CYP1A2 (0.42) | KDM4EALDH1A1BRAFCYP1A2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | claimed |
| EP-4479032-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | Sage Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| CN-116981450-A | Combination of antidepressants and dextromethorphan for the treatment of neuropsychiatric disorders | 安泰赛普生物风投二代有限责任公司 | 2023-10-31 | — | — | CN | claimed |
| WO-2023164385-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023163879-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023164386-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023164387-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. (US) | 2023-08-31 | — | — | WO | claimed |
| WO-2023158668-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| WO-2023159035-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | claimed |
| US-20250295674-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | SAGE THERAPEUTICS, INC. | 2025-09-25 | — | — | US | disclosed |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | SAGE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-3368040-B1 | METHODS AND COMPOSITIONS FOR RECOVERY FROM STROKE | EIP PHARMA LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220175710-A1 | COMBINATION THERAPY | AKERSHUS UNIVERSITETSSYKEHUS HF (NO) | 2022-06-09 | — | — | US | disclosed |
| EP-3955906-A1 | COMBINATION THERAPY COMPRISING AN FFAR4 AGONIST AND AN ALPHA-7 NACHR AGONIST OR POSITIVE MODULATOR | Akershus Universitetssykehus HF (NO) | 2022-02-23 | — | — | EP | disclosed |
| CN-113993513-A | Combination therapy comprising FFAR4 agonist and alpha-7 NACHR agonist or positive modulator | 阿克斯胡斯大学医院HF | 2022-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170147-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | KDM4E 4740/4885ALDH1A1 1825/4885BRAF 3230/4885 |
| US-20250170149-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | KDM4E 4740/4885ALDH1A1 1825/4885BRAF 3230/4885 |
| US-20250177418-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | KDM4E 4740/4885ALDH1A1 1825/4885BRAF 3230/4885 |
| US-20250170148-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF GASTROINTESTINAL DISEASES OR CONDITIONS | MC2R, CRH, NTSR2 | KDM4E 4740/4885ALDH1A1 1825/4885BRAF 3230/4885 |
| US-20250295674-A1 | NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS | CRH, GAP43, SLC18A2 | KDM4E 4054/4885ALDH1A1 1516/4885BRAF 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.